Ohnmacht G A, Wang E, Mocellin S, Abati A, Filie A, Fetsch P, Riker A I, Kammula U S, Rosenberg S A, Marincola F M
Surgery Branch, Department of Transfusion Medicine, Clinical Center, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
J Immunol. 2001 Aug 1;167(3):1809-20. doi: 10.4049/jimmunol.167.3.1809.
The melanoma patient's immune response to tumor has been extensively studied. Yet, the frequently observed coexistence of tumor-associated Ag (TAA)-specific T cells with their target cells in vivo remains unexplained. Loss of TAA expression might contribute to this paradox. We studied TAA expression in metastases by obtaining fine-needle aspirations from 52 tumor lesions in 30 patients with melanoma before and soon after immunotherapy. Limitations due to low amounts of starting material were overcome with a high fidelity antisense RNA amplification method. TAA expression was measured by quantitative real-time PCR of anti-sense RNA. Decrease in gp100/Pmel-17 TAA preceded tumor disappearance in several instances and could be best explained by immune selection because most patients had received gp100/Pmel-17-specific vaccination. Conversely, immune selection was absent in nonregressing lesions. These observations suggest that vaccination, when successful, triggers a broad inflammatory reaction that can lead to tumor destruction despite immune selection. Additionally, lack of clinical response might be attributed to lack of this initiating event rather than immune escape. This study provides an insight into the natural history of tumors and defines a strategy for the characterization of gene expression in tumors during therapy.
黑色素瘤患者对肿瘤的免疫反应已得到广泛研究。然而,肿瘤相关抗原(TAA)特异性T细胞与其靶细胞在体内经常同时存在,这一现象仍无法解释。TAA表达缺失可能是造成这一矛盾现象的原因。我们通过对30例黑色素瘤患者的52个肿瘤病灶进行细针穿刺,获取免疫治疗前后的样本,研究转移灶中的TAA表达。采用高保真反义RNA扩增方法克服了起始材料量少带来的局限性。通过反义RNA的定量实时PCR检测TAA表达。在几个病例中,gp100/Pmel-17 TAA的减少先于肿瘤消失,这最好用免疫选择来解释,因为大多数患者接受了gp100/Pmel-17特异性疫苗接种。相反,在无消退的病灶中不存在免疫选择。这些观察结果表明,疫苗接种成功时,会引发广泛的炎症反应,尽管存在免疫选择,但仍可导致肿瘤破坏。此外,缺乏临床反应可能归因于缺乏这种起始事件,而非免疫逃逸。本研究深入了解了肿瘤的自然史,并确定了一种在治疗期间表征肿瘤基因表达的策略。